[ CancerWeb Home
| Comments
| Up One Level ]
Original Summaries of Selected CANCERLIT Records
Diagnosis of Prostate Cancer by PSA Coupled with ACP
Last modified on:
Tuesday, April 20, 1999 10:52:30
Copyright © 1994-2008, Information Ventures, Inc.
While PSA is currently the major surrogate marker, other tests that
were once used may still have application in multiple marker
trials. A group at Memorial Sloan-Kettering Cancer Center in New
York (Kelly; ICDB/95613759), investigated among 107 patients with
androgen independent prostate cancer those who had a 50% or 80%
decline in PSA, acid phosphatase (ACP), alkaline phosphatase, and
lactate dehydrogenase after treatment. Decline in PSA following
treatment preceded any falls in the other markers including ACP.
Seventeen patients had a 50% decline and 10 patients had an 80%
decline in PSA with median survivals of 26.5 and 28.1 mo,
respectively, while 15 patients had a 50% decline and four had an
80% decline in ACP, with median survival of 26.5 and 25.3 mo,
respectively. Overall, 13 patients had a decline of both PSA and
ACP, while only two had a 50% decline of ACP with no corresponding
decline in PSA. The authors suggested that the simultaneous use of
a 50% decline of ACP with PSA provides further definition of those
patients with improved survival prospects, and could serve as
surrogate markers for Phase III trials.
November, 1995
Copyright (c) 1994-2008, Information Ventures, Inc.
Mail us at: Customer-Service@infoventures.com
http://infoventures.com